Proteases have been implicated in tumor progression but PAR1 may be a good example of protease effectors implicated in tumour invasion and metastasis development and in a near future, PAR1 could become an ideal candidate for assessing new targets for drugs in the early diagnosis and treatment of metastasis in breast cancer patients. Here, F2R is linked to breast carcinoma.